Trial Profile
phase I study of radiosensitization using bortezomib in patients with relapsed mantle cell or aggressive lymphoma receiving radioimmunotherapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Tositumomab (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 25 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Mar 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 12 Feb 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov, last updated 12 Feb 2009.